FDA OKs etravirine as treatment for HIV

The FDA has cleared etravirine, a non-nucleoside reverse transcriptase inhibitor, as combination treatment for HIV infection in adults who fail to respond to other antiretrovirals. Johnson & Johnson unit Tibotec Therapeutics will market the drug under the brand Intelence.

View Full Article in:

Boston Globe (tiered subscription model), The · NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC